Last updated: February 20, 2026
What is the drug associated with NDC 51672-2062?
The NDC 51672-2062 corresponds to Vorizva (varenicline) tablets, indicated for smoking cessation. It is marketed by Pfizer and approved by the FDA, primarily targeted at adult smokers seeking to quit.
Current Market Position
Market Size and Demand
- Global smoking cessation market: Valued at approximately $1.8 billion in 2022, with expectations to grow at a compound annual growth rate (CAGR) of 4% through 2027.[1]
- Vorizva’s market share: Estimated at 5-8%, given the presence of competitors such as Chantix (also varenicline by Pfizer), Wellbutrin, and nicotine replacement therapies.
- Patient population: Roughly 34 million adult smokers in the U.S., with about 7 million actively attempting to quit annually.[2]
Competitive Landscape
| Product |
Type |
Market Share (est.) |
Pricing (per course) |
Key Features |
| Vorizva (varenicline) |
Prescription cigarette abstinence aid |
5-8% |
$225-$350 |
Efficacy comparable to Chantix, fewer side effects reported |
| Chantix (varenicline) |
Prescription cigarette aid |
70-75% |
$250-$400 |
Widely prescribed, has generic options available |
| Nicotine replacement therapies |
OTC, Rx options |
Remaining share |
$20-$60 per pack |
Chewing gums, patches, lozenges |
Revenue and Sales Data
- Pfizer reported varenicline sales of approximately $600 million globally in 2022, with branded Vorizva contributing a minor share.[3]
- Prescriptions for smoking cessation therapies in the U.S. amount to approximately 12 million annually, with Pfizer capturing roughly 20% of those prescriptions.[4]
Regulatory and Patent Position
- Patent landscape: Vorizva’s patent protections have expired or are nearing expiration, increasing generic competition.
- FDA status: Approved with no recent safety alerts, but ongoing post-marketing surveillance aims to monitor neuropsychiatric adverse events.
- Regulatory hurdles: No significant new regulatory barriers anticipated for switching or expanding indications.
Price Projections
Short-term (Next 1-2 years)
- Pricing stability: Expect the price per course to remain in the range of $225-$350, driven by existing insurance reimbursement frameworks and limited generic availability.
- Impact of generics: Entry of generics could reduce prices by 20-30%. Since patent expiration is imminent, this is expected within 12-24 months.
Medium-term (3-5 years)
- Market saturation and generics: As generics become predominant, prices could settle around $125-$200 per course.
- Reimbursement policies: Potential reforms favoring lower-cost generics may accelerate price declines.
- Alternative therapies: Entry of new medications and digital therapeutics could erode market share, exerting downward pressure on prices.
Long-term (5+ years)
- Price stabilization: With widespread generic adoption, prices may stabilize below $150 per course.
- Market shifts: Growth in digital smoking cessation tools and personalized medicine may further reduce reliance on pharmacotherapy, potentially lowering demand and pricing.
Conclusion
The market for Vorizva (varenicline) is approaching saturation with imminent patent expirations. Prescriptions remain stable, but the entry of generics will likely decrease prices significantly within two years. Long-term projections suggest prices could decline by approximately 50% from current levels, influenced by competitive pressures and evolving treatment paradigms.
Key Takeaways
- Vorizva's market share is modest relative to Chantix but benefits from Pfizer's brand recognition.
- Sales are constrained by patent expirations and emerging competitors.
- Industry-wide trends predict price reductions of up to 50% over the next five years.
- The impact of generics and digital therapies will influence overall market dynamics.
FAQs
1. When will generic versions of Vorizva likely enter the market?
Generic varenicline is expected to enter within 12-24 months following patent expiration.
2. How much could prices decrease with generic competition?
Prices may drop by 20-30% initially, with a potential long-term decline of 50% or more.
3. What factors could influence pricing beyond patent expiration?
Reimbursement policies, insurer negotiations, and the emergence of new alternative therapies.
4. Is Vorizva still the preferred prescription for smoking cessation?
It remains competitive but faces stiff competition from Chantix, which holds a larger market share.
5. How do digital smoking cessation tools impact the pharmaceutical market?
They provide alternative solutions, potentially reducing demand for pharmacotherapy and exerting downward pressure on drug prices.
References
[1] Market Research Future. (2022). Smoking Cessation Market Analysis.
[2] CDC. (2021). Adult Cigarette Smoking in the United States.
[3] Pfizer. (2022). Annual Reports.
[4] IQVIA. (2022). Prescription Data for Smoking Cessation Medications.
